Pharming Group (PHAR)
9.800
-0.65
(-6.22%)
USD |
NASDAQ |
Apr 26, 16:00
9.55
-0.25
(-2.55%)
After-Hours: 20:00
Pharming Group Enterprise Value: 584.99M for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 584.99M |
| April 25, 2024 | 628.74M |
| April 24, 2024 | 586.99M |
| April 23, 2024 | 571.50M |
| April 22, 2024 | 593.05M |
| April 19, 2024 | 598.44M |
| April 18, 2024 | 553.32M |
| April 17, 2024 | 609.88M |
| April 16, 2024 | 609.88M |
| April 15, 2024 | 650.96M |
| April 12, 2024 | 634.13M |
| April 11, 2024 | 685.98M |
| April 10, 2024 | 630.76M |
| April 09, 2024 | 598.44M |
| April 08, 2024 | 642.21M |
| April 05, 2024 | 638.84M |
| April 04, 2024 | 644.90M |
| April 03, 2024 | 663.09M |
| April 02, 2024 | 649.62M |
| April 01, 2024 | 685.00M |
| March 28, 2024 | 652.44M |
| March 27, 2024 | 652.44M |
| March 26, 2024 | 653.11M |
| March 25, 2024 | 681.30M |
| March 22, 2024 | 681.30M |
| Date | Value |
|---|---|
| March 21, 2024 | 663.18M |
| March 20, 2024 | 663.18M |
| March 19, 2024 | 663.18M |
| March 18, 2024 | 696.73M |
| March 15, 2024 | 695.98M |
| March 14, 2024 | 657.81M |
| March 13, 2024 | 670.56M |
| March 12, 2024 | 722.23M |
| March 11, 2024 | 706.80M |
| March 08, 2024 | 697.07M |
| March 07, 2024 | 676.60M |
| March 06, 2024 | 676.60M |
| March 05, 2024 | 673.92M |
| March 04, 2024 | 716.19M |
| March 01, 2024 | 687.93M |
| February 29, 2024 | 693.37M |
| February 28, 2024 | 669.89M |
| February 27, 2024 | 673.92M |
| February 26, 2024 | 681.97M |
| February 23, 2024 | 713.51M |
| February 22, 2024 | 713.51M |
| February 21, 2024 | 672.53M |
| February 20, 2024 | 663.85M |
| February 16, 2024 | 676.60M |
| February 15, 2024 | 665.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
376.23M
Minimum
Jun 16 2022
1.027B
Maximum
Dec 23 2020
665.05M
Average
685.38M
Median
Sep 30 2023
Enterprise Value Benchmarks
| uniQure NV | -299.44M |
| ProQR Therapeutics NV | 31.11M |
| Merus NV | 2.273B |
| argenx SE | 18.98B |
| Pharvaris NV | 824.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.123M |
| Revenue (Quarterly) | 81.22M |
| Total Expenses (Quarterly) | 96.76M |
| EPS Diluted (Quarterly) | -0.05 |
| Gross Profit Margin (Quarterly) | 91.24% |
| Profit Margin (Quarterly) | -3.85% |
| Earnings Yield | -1.63% |
| Normalized Earnings Yield | -1.633 |